Hundreds of thousands of Americans are fighting lung cancer. And the number is growing, with 25 cases diagnosed every hour.* Like fingerprints, lung cancer is
unique and no two people have the exact same type of lung cancer. Unfortunately,
treatments are not always tailored to a person’s unique tumor, wasting precious time
in the battle against the disease. But individuals with lung cancer have options.
Comprehensive genomic testing can reveal the genomic makeup of your
lung cancer, usually in about two weeks, and direct specialized treatment options
that could help manage your disease.
* Source: Lung Cancer Research Council
A comprehensive genomic profiling test looks at all type of genomic alterations across all of the cancer-related genes in a single sample of tumor tissue. This allows for the identification of multiple genomic alterations present in the tumor that may lead to targeted treatment options you may consider.
Genomic tests are designed to analyze any type of tumor regardless of where it is found in the body or how advanced the cancer. And the tests are generally used for more advanced disease or disease that has spread. Talk with your doctor to see if genomic testing is right for you.
When fighting cancer, time is of the essence. Using a single tissue sample, the FoundationOne® comprehensive genomic test simultaneously probes hundreds of cancer-related genes in a tumor.
Alternatively, your physician may determine that the FoundationACT™ test is appropriate for you if a tissue biopsy may not be feasible. Within 10-14 days, your doctor will receive FoundationOne or FoundationACT results that may help identify the most effective treatment for your lung cancer, including targeted therapies, immunotherapies and clinical trials.
By contrast, limited gene “hotspot” tests or single-gene tests can require numerous tissue samples. This takes more time, more tissue and may only deliver a fraction of the information provided by a comprehensive genomic test.
Physician orders the FoundationOne Test
Foundation Medicine receives the patient’s tumor sample and extracts DNA from the sample
Experts determine the unique genomic makeup of the tumor
The FoundationOne report is delivered to your physician and may identify unique alterations that can help direct your physician to useful targeted therapies, immunotherapies or clinical trials
Download Questions to Ask Your Doctor